Efficacy and safety of alisporivir for the treatment of hepatitis C infection. (4th March 2019)

• Record Type: Journal Article
• Authors: Stanciu, Carol; Trifan, Anca; Muzica, Cristina; Sfarti, Catalin
• Is Part Of: Expert opinion on pharmacotherapy. Volume 20:Number 4(2019)
• Page Start: 379
• Page End: 384
• Publication Date: 2019-03-04
• Subjects: Alisporivir -- cyclophilin A -- hepatitis C -- side effects -- treatment; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2018.1560424
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Alisporivir (ALV) (previously known as Debio 025) is a potent, pangenotypic host-targeting antiviral oral agent acting on cyclophilin A, which is necessary for HCV replication. Areas covered : This article reviews the therapeutic efficacy and safety of ALV for the treatment of HCV infection. Expert opinion : Direct-acting antivirals (DAAs) have revolutionized the HCV antiviral treatment paradigm with success rates well above 95% for all HCV genotypes. However, challenges still remain in certain patient populations such as those who have developed resistance and have experienced multi-DAA failure. To cure HCV infection, a treatment regimen must combine antiviral potency and a high barrier to resistance. ALV fulfills this need as shown by the studies evaluating its clinical efficacy. Nevertheless, ALV missed the chance to be included in the HCV treatment armamentarium after the FDA halted clinical studies following reports of serious side effects (three cases of pancreatitis, one lethal). However, it is possible that ALV could still be considered for HCV-infected non-cirrhotic patients that are infected with a multiresistant virus or with HCV genotype 3, although it must be said that the drug industry would be reluctant to invest in new antivirals if the current clinical need is effectively met.